Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: A game of stop and go

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Vasaturo, Angela ^a   Di Blasio, Stefania ^a   Peeters, Deborah G A ^a   de Koning, Coco C H ^a   de Vries, Jolanda M ^a   Figdor, Carl G ^a   Hato, Stanleyson V ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer treatment; Checkpoint blockade; DC vaccination; Tumor microenvironment; Tumor specific T cells

Indexed keywords

EID: 84892171528     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00417     Document Type: Review

References (138)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 331(6024):1565-70. doi: 10.1126/science.1203486.
2. Bakdash G, Sittig SP, van Dijk T, Figdor CG, de Vries IJ. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol (2013) 4:53. doi:10.3389/fimmu.2013.00053.
3. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12(4):265-77. doi:10.1038/nrc3258.
4. Schreibelt G, Bol KF, Aarntzen EH, Gerritsen WR, Punt CJ, Figdor CG, et al. Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. Oncoimmunology (2013) 2(6):e24440. doi:10.4161/onci.24440.
5. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res (2011) 50(2-3):248-54. doi:10.1007/s12026-011-8231-0.
6. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sörensen A, Seder RA, et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol (2009) 182(4):1991-2001. doi:10.4049/jimmunol.0802257.
7. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. Biomed Res Int (2012) 2012:425476. doi:10.1155/2012/425476.
8. Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs (2009) 10(6):526.
9. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today (1998) 19(12):568-74. doi:10.1016/S0167-5699(98)01346-2.
10. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 2012:926321. doi:10.1155/2012/926321.
11. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 10(5):475-80. doi:10.1038/nm1039.
12. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol (1997) 158(6):2723-30.
13. Cahalan MD, Parker I, editors. Close encounters of the first and second kind: T-DC and T-B interactions in the lymph node. Semin Immunol (2005) 17(6):442-51. doi:10.1016/j.smim.2005.09.001.
14. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, et al. Immature dendritic cells acquire Cd8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or-dependent stimuli. J Exp Med (2000) 192(1):145-50. doi:10.1084/jem.192.1.145.
15. Bhardwaj N, Friedman SM, Cole BC, Nisanian A. Dendritic cells are potent antigen-presenting cells for microbial superantigens. J Exp Med (1992) 175(1):267-73. doi:10.1084/jem.175.1.267.
16. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med (1994) 180(5):1841-7. doi:10.1084/jem.180.5.1841.
17. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity (1994) 1(6):501-8. doi:10.1016/1074-7613(94)90092-2.
18. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev (2010) 238(1):247-62. doi:10.1111/j.1600-065X.2010.00951.x.
19. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol (2008) 9(9):981-7. doi:10.1038/ni.f.208.
20. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 18(19):5460-70. doi:10.1158/1078-0432.CCR-11-3368.
21. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 73(3):1063-75. doi:10.1158/0008-5472.CAN-12-2583.
22. Kreutz M, Tacken PJ, Figdor CG. Targeting dendritic cells-why bother? Blood (2013) 121(15):2836-44. doi:10.1182/blood-2012-09-452078.
23. Aarntzen EH, de Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2013) 73(1):19-29. doi:10.1158/0008-5472.CAN-12-1127.
24. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 115(16):3670-9. doi:10.1002/cncr.24429.
25. Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J. Building on dendritic cell subsets to improve cancer vaccines. Curr Opin Immunol (2010) 22(2):258-63. doi:10.1016/j.coi.2010.02.010.
26. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 17(17):5725-35. doi:10.1158/1078-0432.CCR-11-1261.
27. Gilboa E. DC-based cancer vaccines. J Clin Invest (2007) 117(5):1195-203. doi:10.1172/JCI31205.
28. Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 11(1):149. doi:10.1186/1479-5876-11-149.
29. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1(7):1111-34. doi:10.4161/onci.21494.
30. Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, et al. Letal, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther (2003) 2(4):446-51.
31. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 9(4):212. doi:10.1186/bcr1746.
32. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev (2007) 26(3-4):373-400. doi:10.1007/s10555-007-9072-0.
33. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol (2006) 12(45):7233-8.
34. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506.
35. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12(4):253-68. doi:10.1038/nri3175.
36. Teng MW, Ritchie DS, Neeson P, Smyth MJ. Biology and clinical observations of regulatory T cells in cancer immunology. Curr Top Microbiol Immunol (2011) 344:61-95. doi:10.1007/82_2010_50.
37. Linsley PS, Greene J, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 176(6):1595-604. doi:10.1084/jem.176.6.1595.
38. Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation. J Exp Med (2000) 192(2):295-302. doi:10.1084/jem.192.2.295.
39. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 229(1):126-44. doi:10.1111/j.1600-065X.2009.00771.x.
40. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 174(3):561-9. doi:10.1084/jem.174.3.561.
41. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 183(6):2533-40. doi:10.1084/jem.183.6.2533.
42. Walunas TL, Bakker C, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 183(6):2541-50. doi:10.1084/jem.183.6.2541.
43. Alegre M-L, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol (1996) 157(11):4762-70.
44. Ubaldi V, Gatta L, Pace L, Doria G, Pioli C. CTLA-4 engagement inhibits Th2 but not Th1 cell polarisation. Clin Dev Immunol (2003) 10(1):13-7. doi:10.1080/10446670310001598519.
45. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol (2000) 46(Suppl):S52-61. doi:10.1007/PL00014051.
46. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in TH2 lineage commitment. Nat Immunol (2003) 4(2):182-8. doi:10.1038/ni884.
47. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 8(5):765-72. doi:10.1093/intimm/8.5.765.
48. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 206(13):3015-29. doi:10.1084/jem.20090847.
49. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11(2):141-51. doi:10.1016/S1074-7613(00)80089-8.
50. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192(7):1027-34. doi:10.1084/jem.192.7.1027.
51. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677-704. doi:10.1146/annurev.immunol.26.021607.090331.
52. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8(8):793-800. doi:10.1038/nm0902-1039c.
53. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 5(12):1365-9. doi:10.1038/70932.
54. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 2(3):261-8. doi:10.1038/85330.
55. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol (2005) 23:515-48. doi:10.1146/annurev.immunol.23.021704.115611.
56. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 9(5):562-7. doi:10.1038/nm863.
57. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 99(19):12293-7. doi:10.1073/pnas.192461099.
58. Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, et al. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology (2012) 1(7):1061-73. doi:10.4161/onci.20850.
59. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 27(1):111-22. doi:10.1016/j.immuni.2007.05.016.
60. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 2012:656340. doi:10.1155/2012/656340.
61. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 13(18):5271-9. doi:10.1158/1078-0432.CCR-07-1030.
62. Fauci JM, Straughn JM, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol (2012) 127(2):420-5. doi:10.1016/j.ygyno.2012.08.017.
63. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol (2001) 2(3):269-74. doi:10.1038/85339.
64. Sica GL, Choi I-H, Zhu G, Tamada K, Wang S-D, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 18(6):849-61. doi:10.1016/S1074-7613(03)00152-3.
65. Jiang J, Zhu Y, Wu C, Shen Y, Wei W, Chen L, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother (2010) 59(11):1707-14. doi:10.1007/s00262-010-0900-7.
66. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 103(27):10391-6. doi:10.1073/pnas.0600937103.
67. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev (2009) 229(1):145-51. doi:10.1111/j.1600-065X.2009.00768.x.
68. Ware CF, Šedỳ JR. TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14). Curr Opin Immunol (2011) 23(5):627-31. doi:10.1016/j.coi.2011.08.008.
69. Kojima R, Kajikawa M, Shiroishi M, Kuroki K, Maenaka K. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. J Mol Biol (2011) 413(4):762-72. doi:10.1016/j.jmb.2011.09.018.
70. Croft M. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA. Trends Immunol (2005) 26(6):292-4. doi:10.1016/j.it.2005.03.010.
71. Cella M, Döhring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med (1997) 185(10):1743-51. doi:10.1084/jem.185.10.1743.
72. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, et al. Cutting edge: human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol (1998) 160(7):3096-100.
73. Vlad G, D'Agati VD, Zhang Q-Y, Liu Z, Ho EK, Mohanakumar T, et al. Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice. Diabetes (2008) 57(7):1878-86. doi:10.2337/db08-0054.
74. Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom (2013) 84(1):21-9. doi:10.1002/cyto.b.21050.
75. Suciu-Foca N, Feirt N, Zhang Q-Y, Vlad G, Liu Z, Lin H, et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol (2007) 178(11):7432-41.
76. Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci (2013) 1284(1):24-30. doi:10.1111/nyas.12113.
77. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol (2012) 24(2):213-6. doi:10.1016/j.coi.2011.12.005.
78. Workman CJ, Cauley LS, Kim I-J, Blackman MA, Woodland DL, Vignali DA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol (2004) 172(9):5450-5.
79. Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity (2004) 21(4):503-13. doi:10.1016/j.immuni.2004.08.010.
80. Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 182(4):1885-91. doi:10.4049/jimmunol.0800185.
81. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 107(17):7875-80. doi:10.1073/pnas.1003345107.
82. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 355(10):1018-28. doi:10.1056/NEJMoa063842.
83. Pardoll Drew DC. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 209(2):201-9. doi:10.1084/jem.20112275.
84. Ascierto PA, Simeone E, Sznol M, Fu Y-X, Melero I, editors. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 37(5):508-16. doi:10.1053/j.seminoncol.2010.09.008.
85. Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma (2013) 54(10):2144-8. doi:10.3109/10428194.2013.775434.
86. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 25(2):230-7. doi:10.1016/j.coi.2013.01.004.
87. Goldwater R, Keirns J, Blahunka P, First R, Sawamoto T, Zhang W, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant (2013) 13(4):1040-6. doi:10.1111/ajt.12082.
88. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3(5):541-7. doi:10.1016/1074-7613(95)90125-6.
89. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 270(5238):985-8. doi:10.1126/science.270.5238.985.
90. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271(5256):1734-6. doi:10.1126/science.271.5256.1734.
91. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466.
92. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364(26):2517-26. doi:10.1056/NEJMoa1104621.
93. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 31(5):616-22. doi:10.1200/JCO.2012.44.6112.
94. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 100(14):8372-7. doi:10.1073/pnas.1533209100.
95. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 23(35):8968-77. doi:10.1200/JCO.2005.01.109.
96. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi:10.1038/nrc3239.
97. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2012) 61(7):1019-31. doi:10.1007/s00262-011-1172-6.
98. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 13:5.
99. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 28(19):3167-75. doi:10.1200/JCO.2009.26.7609.
100. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2013) 19(2):462-8. doi:10.1158/1078-0432.CCR-12-2625.
101. Sosman J, Sznol M, McDermott DF, Carvajal R, Lawrence DP, Topalian SL, et al. Melanoma and other skin tumors. Ann Oncol (2012) 23(Suppl 9):ix361-75. doi:10.1093/annonc/mds404.
102. Sosman J, Sznol M, McDermott DF, Carvajal R, Lawrence DP, Topalian SL, et al. Clinical activity and safety of anti-programmed death-1 (Pd-1) (Bms-936558/Mdx-1106/Ono-4538) in patients with advanced melanoma. In: Meeting Abstract: 1109O-37th Congress of the European-Society-for-Medical-Oncology (ESMO) Vienna: Oxford University Press (2012). 361 p.
103. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690.
104. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134-44. doi:10.1056/NEJMoa1305133.
105. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 14(10):3044-51. doi:10.1158/1078-0432.CCR-07-4079.
106. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366(26):2455-65. doi:10.1056/NEJMoa1200694.
107. Loos M, Hedderich DM, Friess H, Kleeff J. B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 2010:683875. doi:10.1155/2010/683875.
108. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer (2006) 53(2):143-51. doi:10.1016/j.lungcan.2006.05.012.
109. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 14(16):5150-7. doi:10.1158/1078-0432.CCR-08-0536.
110. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer (2009) 9(1):463. doi:10.1186/1471-2407-9-463.
111. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol (2004) 173(4):2500-6.
112. Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 18(14):3834-45. doi:10.1158/1078-0432.CCR-12-0715.
113. Leung J, Suh WK. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J Immunol (2013) 190(12):6651-61. doi:10.4049/jimmunol.1201242.
114. Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, et al. Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T cell anti-tumor responses. Cancer Res (2013) 73(15):4820-9. doi:10.1158/0008-5472.CAN-12-3457.
115. Cortesini R. Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). JOP (2007) 8:697-703.
116. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 71(10):3540-51. doi:10.1158/0008-5472.CAN-11-0096.
117. Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, et al. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother (2013) 62(4):629-37. doi:10.1007/s00262-012-1371-9.
118. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369(2):122-33. doi:10.1056/NEJMoa1302369.
119. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2012) 72(4):887-96. doi:10.1158/0008-5472.CAN-11-2637.
120. Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2012) 72(4):917-27. doi:10.1158/0008-5472.CAN-11-1620.
121. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 96(20):11476-81. doi:10.1073/pnas.96.20.11476.
122. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett (2006) 231(2):247-56. doi:10.1016/j.canlet.2005.02.005.
123. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 95(17):10067-71. doi:10.1073/pnas.95.17.10067.
124. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (Ctla-4) and granulocyte/macrophage colony-stimulating factor (Gm-Csf)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med (1999) 190(3):355-66.
125. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol (2009) 183(6):3634-41. doi:10.4049/jimmunol.0900974.
126. Pilon-Thomas S, Mackay A, Vohra N, Mulé JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 184(7):3442-9. doi:10.4049/jimmunol.0904114.
127. Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett (2013) 336(2):253-9. doi:10.1016/j.canlet.2013.03.010.
128. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 13(5):509-17. doi:10.1016/S1470-2045(12)70007-4.
129. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 368(14):1365-6. doi:10.1056/NEJMc1302338.
130. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 18(7):2039-47. doi:10.1158/1078-0432.CCR-11-1823.
131. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 25:B97-109. doi:10.1016/j.vaccine.2007.06.067.
132. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 15(19):6267-76. doi:10.1158/1078-0432.CCR-09-1254.
133. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (2004) 27(5):354-67. doi:10.1097/00002371-200409000-00004.
134. Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, et al. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 2(6):e23972. doi:10.4161/onci.23972.
135. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest (2009) 119(8):2127-30. doi:10.1172/JCI39991.
136. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 121(8):3100. doi:10.1172/JCI43656.
137. Hato SV, de Vries IJ, Lesterhuis WJ. STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology (2012) 1(2):234-6. doi:10.4161/onci.1.2.18126.
138. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother (2013) 62(3):405-10. doi:10.1007/s00262-012-1390-6.